Alpha Tau Medical Ltd. Ordinary Shares
DRTSAlpha Tau Medical Ltd. is a biotechnology company specializing in innovative cancer treatment solutions. It developed the Alpha DaRT (Diffuse Dopant RadioTherapy), a novel radiation therapy that combines targeted radioactive sources with standard treatment protocols to enhance cancer cell destruction. The company focuses on advancing minimally invasive therapies with potential applications across various tumor types.
Company News
Alpha Tau Medical Ltd. announced the completion of enrollment of 88 patients in its ReSTART pivotal trial for treating recurrent cutaneous squamous cell carcinoma (cSCC) with Alpha DaRT®. This marks the company's first completed U.S. pivotal study and a critical milestone toward FDA pre-market approval. The company has already initiated a modula...
Alpha Tau Medical will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026, discussing recent achievements and upcoming data milestones for their Alpha DaRT cancer therapy.
The global radiopharmaceuticals market is projected to grow at a CAGR of 10.3% from 2024 to 2030, driven by the increasing prevalence of chronic diseases, advancements in imaging technology, and the transition towards personalized medicine. North America and Asia-Pacific are the key regional markets.
Alpha Tau Medical Ltd. announced the appointment of Maya Netser to its Board of Directors, while Meir Jakobsohn is stepping down from the Board but will continue to serve as an advisor.
TIMB, AKYA, DRTS, TRUP and QSG have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.
